+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Vaccines Market By Indication (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR), Type (Live, Toxoid), Route Of Administration (IM, SC, Oral), Valence (Monovalent, Multivalent) & Geography – Global Forecast to 2025

  • ID: 4708809
  • Report
  • Region: Global
  • 149 Pages
  • Meticulous Market Research Pvt. Ltd.
UP TO OFF
until Dec 31st 2019
1 of 4
Vaccines Market Worth $57.5 Billion By 2025

FEATURED COMPANIES

  • AstraZeneca
  • CSL Limited
  • Daiichi Sankyo
  • Emergent Biosolutions
  • GSK
  • Johnson and Johnson
  • MORE

Vaccines Market by Indication (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR), Type (Live, Toxoid), Route of Administration (IM, SC, Oral), Valence (Monovalent, Multivalent) and Geography–Global Forecast to 2025

The global vaccines market is expected to reach $57.50 billion by 2025 from $33.70 billion in 2018, growing at a CAGR of 7.9%. The growth of this market is mainly attributed to high prevalence of diseases, increasing government initiatives towards immunization, rising adoption of vaccines, technological advancements in vaccine industry, and strong pipeline for vaccines. In addition, increasing epidemic potentials and growing focus on therapeutic vaccines are expected to offer significant growth opportunities for players operating in the vaccines market. However, the high costs associated with vaccine development, stringent regulations and a longer timeline for vaccine development, as well as product recalls, are expected to hinder the growth of this market to a certain extent. On the other hand, the new product development cycle for vaccines and need for more training dedicated to vaccinology pose a major challenge for vaccines industry.

In 2017, pneumococcal disease accounted for the largest share of the vaccines market. The large share of this segment is mainly attributed to high prevalence of pneumococcal disease in pediatric, elderly, and immunocompromised populations. In addition, growing number of pneumococcal diseases associated with chronic disease patients is further driving the adoption of the pneumococcal vaccines.

The route of administration is the lane by which a vaccine is brought into contact with the body. Vaccines are administered through Intramuscular (IM), Subcutaneous (SC/SQ), oral, and others (intradermal and nasal). In 2017, the intramuscular accounted for the largest share of the of the global vaccines market. The large share of this segment is mainly due to availability of wide range of vaccines for IM.

Subunit, recombinant, polysaccharide, and conjugate vaccines accounted for the largest share of the global vaccines market in 2017. The large share of this segment is mainly attributed to increasing focus of companies towards recombinant and conjugate vaccines, growing prevalence of diseases, and increasing government initiatives.

An in-depth analysis of the geographical scenario of the industry provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region.

North America accounted for largest share of vaccines market in 2017. The large share of this segment is mainly attributed to the well established vaccination program in the region, increasing prevalence of diseases, growing adoption of advanced vaccines, and large pool of key players.

The Asia-Pacific vaccines market is expected to grow at a highest CAGR of 8.9%. The growth in the APAC market is mainly attributed to large patient pool, rising prevalence of diseases, growing awareness on vaccination, increasing government initiatives, and expanding presence of key players in this region. In addition, factors such as increasing disposable income and growing awareness about heath in emerging countries are further propelling the demand of vaccines in APAC.

The report includes competitive landscape based on extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past 3 years (2015-2018). The key players profiled in the global vaccines market research report are GSK, Merck & Co., Inc., Pfizer, Sanofi, CSL Limited, Emergent Biosolutions, Johnson and Johnson, Serum Institute of India, Daiichi Sankyo, Takeda, and AstraZeneca.

Scope of the Report:

Market by Indication

  • Pneumococcal Disease
  • Influenza
  • DTP
  • Polio
  • HPV
  • MMR
  • Rotavirus
  • Meningococcal Disease
  • Hepatitis
  • Others

Market by Route of Administration

  • Intramuscular (IM
  • Subcutaneous (SC/SQ)
  • Oral
  • Others (Intradermal and Nasal)

Market by Type

  • Subunit, recombinant, polysaccharide, and conjugate vaccines
  • Inactivated vaccines
  • Live-attenuated vaccines
  • Toxoid vaccines

Market by Valent

  • Monovalent
  • Multivalent

Market by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • U.K.
    • Italy
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • China
    • Japan
    • India
    • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East and Africa
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • CSL Limited
  • Daiichi Sankyo
  • Emergent Biosolutions
  • GSK
  • Johnson and Johnson
  • MORE

1. Introduction
1.1. Market Definition
1.2. Market Segmentation
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Key Stakeholders

2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
2.1.2. Primary Research
2.1.3. Market Size Estimation

3. Executive Summary
3.1. Introduction
3.2. Market Dynamics
3.3. Product Segment Analysis
3.4. Regional Market Analysis
3.5. Competitive Analysis

4. Market Insights
4.1. Market Overview
4.2. Market Dynamics
4.3. Drivers
4.3.1. Strong Vaccines Pipeline
4.3.2. Rising Adoption of Vaccination
4.3.3. Increasing Government Focus on Immunization Programs
4.3.4. Technological Progress in Vaccine Administration
4.4. Restraints
4.4.1. High Cost Associated with Vaccine Development
4.4.2. Longer Timelines for Vaccine Manufacturing
4.5. Opportunities
4.5.1. Increasing Epidemic Potentials
4.5.2. Growing Focus on Therapeutic Vaccines
4.5.3. Growth Prospects in Emerging Markets
4.5.4. Increasing Use of Adjuvants in Vaccines
4.6. Challenges
4.6.1. Product Recalls
4.6.2. Inadequate Access to Vaccines

5. Industry Analysis
5.1. Regulatory Analysis
5.2. Pipeline Analysis
5.3. Unmet Needs Analysis
5.4. Pricing Analysis, by Region

6. Global Vaccines Market, by Indication
6.1. Overview
6.2. Pneumococcal Disease
6.3. Influenza
6.4. DTP
6.5. Human Papilloma Virus (HPV)
6.6. Meningococcal Disease
6.7. Poliomyelitis (Polio)
6.8. MMR
6.9. Rotavirus
6.10. Hepatitis
6.11. Others

7. Global Vaccines Market, by Route of Administration
7.1. Overview
7.2. Intramuscular (IM)
7.3. Subcutaneous (SC)
7.4. Oral
7.5. Other (Routes of Administration)

8. Global Vaccines Market, by Type/Antigen
8.1. Overview
8.2. Subunit & Conjugate Vaccines
8.3. Inactivated Vaccines
8.4. Live Attenuated Vaccines
8.5. Toxoid Vaccines

9. Global Vaccines Market, by Valence
9.1. Overview
9.2. Multivalent Vaccines
9.3. Monovalent Vaccines

10. Vaccines Market, by Region
10.1. Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. U.K.
10.3.2. Germany
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Asia Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Rest of Asia Pacific
10.5. Latin America
10.6. Middle East & Africa

11. Competitive Landscape
11.1. Overview
11.2. Competition Matrix
11.3. Market Share Analysis
11.3.1. Market Share Analysis, by Company
11.3.2. Market Share Analysis, by Product

12. Company Profiles
12.1. Sanofi Pasteur
12.2. Merck & Co., Inc.
12.3. GlaxoSmithKline Plc
12.4. Pfizer, Inc.
12.5. Johnson & Johnson
12.6. Daiichi Sankyo
12.7. Takeda Pharmaceutical Co. Ltd.
12.8. CSL Limited
12.9. Emergent BioSolutions Inc.
12.10. AstraZeneca

13. Appendix
13.1. Questionnaire

List of Tables
Table 1 List of Some of the Promising Vaccines in The Pipeline
Table 2 Asp of Key Vaccines, by Region ($ Per Unit)
Table 3 Global Vaccines Market Size, by Indication, 2016–2025 ($ Million)
Table 4 Pneumococcal Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 5 Influenza Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 6 DTP Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 7 Human Papilloma Virus (HPV) Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 8 Meningococcal Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 9 Polio Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 10 MMR Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 11 Rotavirus Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 12 Hepatitis Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 13 Other Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 14 Vaccines Market Size, by Route of Administration, 2016–2025 ($ Million)
Table 15 Intramuscular Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 16 Subcutaneous Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 17 Oral Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 18 Other (Route of Administration) Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 19 Global Vaccines Market Size, by Type, 2016–2025 ($ Million)
Table 20 Subunit & Conjugate Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 21 Inactivated Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 22 Live Attenuated Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 23 Toxoid Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 24 Global Vaccines Market Size, by Valence, 2016–2025 ($ Million)
Table 25 Multivalent Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 26 Monovalent Vaccines Market Size, by Region/Country, 2016–2025 ($ Million)
Table 27 Epidemiology: North America
Table 28 North America: Vaccines Market Size, by Indication, 2016–2025 ($ Million)
Table 29 North America: Vaccines Market Size, by Type, 2016–2025 ($ Million)
Table 30 North America: Market Size, by Valence, 2016–2025 ($ Million)
Table 31 North America: Market Size, by Route of Administration, 2016–2025 ($ Million)
Table 32 Influenza Burden in the U.S.
Table 33 Pfizer Vaccine Pipeline in the U.S.
Table 34 U.S.: Vaccines Market Size, by Indication, 2016–2025 ($ Million)
Table 35 U.S.: Market Size, by Type, 2016–2025 ($ Million)
Table 36 U.S.: Market Size, by Valence, 2016–2025 ($ Million)
Table 37 U.S.: Market Size, by Route of Administration, 2016–2025 ($ Million)
Table 38 Canada: Vaccines Market Size, by Indication, 2016–2025 ($ Million)
Table 39 Canada: Vaccines  Market Size, by Type, 2016–2025 ($ Million)
Table 40 Canada: Vaccines Market Size, by Valence, 2016–2025 ($ Million)
Table 41 Canada: Vaccines Market Size, by Route of Administration, 2016–2025 ($ Million)
Table 42 Epidemiology: Europe
Table 43 Europe: Vaccines Market Size, by Indication, 2016–2025 ($ Million)
Table 44 Europe: Vaccines Market Size, by Type, 2016–2025 ($ Million)
Table 45 Europe: Vaccines Market Size, by Valence, 2016–2025 ($ Million)
Table 46 Europe: Vaccines  Market Size, by Route of Administration, 2016–2025 ($ Million)
Table 47 U.K.: Vaccines Market Size, by Indication, 2016–2025 ($ Million)
Table 48 U.K.: Vaccines Market Size, by Type 2016–2025 ($ Million)
Table 49 U.K.: Vaccines Market Size, by Valence, 2016–2025 ($ Million)
Table 50 U.K.: Vaccines Market Size, by Route of Administration, 2016–2025 ($ Million)
Table 51 Germany: Vaccines Market Size, by Indication, 2016–2025 ($ Million)
Table 52 Germany: Market Size, by Type, 2016–2025 ($ Million)
Table 53 Germany: Market Size, by Valence, 2016–2025 ($ Million)
Table 54 Germany: Market Size, by Route of Administration, 2016–2025 ($ Million)
Table 55 France: Vaccines Market Size, by Indication, 2016–2025 ($ Million)
Table 56 France: Market Size, by Type, 2016–2025 ($ Million)
Table 57 France: Market Size, by Valence, 2016–2025 ($ Million)
Table 58 France: Market Size, by Route of Administration, 2016–2025 ($ Million)
Table 59 Italy: Vaccines Market Size, by Indication, 2016–2025 ($ Million)
Table 60 Italy: Market Size, by Type, 2016–2025 ($ Million)
Table 61 Italy: Market Size, by Valence, 2016–2025 ($ Million)
Table 62 Italy: Market Size, by Route of Administration 2016–2025 ($ Million)
Table 63 Spain: Vaccines Market Size, by Indication, 2016–2025 ($ Million)
Table 64 Spain: Market Size, by Type, 2016–2025 ($ Million)
Table 65 Spain: Market Size, by Valence, 2016–2025 ($ Million)
Table 66 Spain: Market Size, by Route of Administration, 2016–2025 ($ Million)
Table 67 Rest of Europe: Vaccines Market Size, by Indication, 2016–2025 ($ Million)
Table 68 Rest of Europe: Market Size, by Type, 2016–2025 ($ Million)
Table 69 Rest of Europe: Market Size, by Valence, 2016–2025 ($ Million)
Table 70 Rest of Europe: Market Size, by Route of Administration, 2016–2025 ($ Million)
Table 71 Epidemiology: Asia Pacific
Table 72 Asia-Pacific: Vaccines Market Size, by Indication, 2016–2025 ($ Million)
Table 73 Asia-Pacific: Market Size, by Type, 2016–2025 ($ Million)
Table 74 Asia-Pacific: Market Size, by Valence, 2016–2025 ($ Million)
Table 75 Asia-Pacific: Market Size, by Route of Administration, 2016–2025 ($ Million)
Table 76 China: Vaccines Market Size, by Indication, 2016–2025 ($ Million)
Table 77 China: Market Size, by Type, 2016–2025 ($ Million)
Table 78 China: Market Size, by Valence, 2016–2025 ($ Million)
Table 79 China: Market Size, by Route of Administration, 2016–2025 ($ Million)
Table 80 Japan: Vaccines Market Size, by Indication, 2016–2025 ($ Million)
Table 81 Japan: Market Size, by Type, 2016–2025 ($ Million)
Table 82 Japan: Market Size, by Valence, 2016–2025 ($ Million)
Table 83 Japan: Market Size, by Route of Administration, 2016–2025 ($ Million)
Table 84 India: Vaccines Market Size, by Indication, 2016–2025 ($ Million)
Table 85 India: Market Size, by Type, 2016–2025 ($ Million)
Table 86 India: Market Size, by Valence, 2016–2025 ($ Million)
Table 87 India: Market Size, by Route of Administration, 2016–2025 ($ Million)
Table 88 Rest of Asia-Pacific: Market Size, by Indication, 2016–2025 ($ Million)
Table 89 Rest of Asia-Pacific: Market Size, by Type, 2016–2025 ($ Million)
Table 90 Rest of Asia-Pacific: Market Size, by Valence, 2016–2025 ($ Million)
Table 91 Rest of Asia-Pacific: Market Size, by Route of Administration, 2016–2025 ($ Million)
Table 92 Epidemiology: Latin America
Table 93 Latin America: Vaccines Market Size, by Indication, 2016–2025 ($ Million)
Table 94 Latin America: Market Size, by Type, 2016–2025 ($ Million)
Table 95 Latin America: Market Size, by Valence, 2016–2025 ($ Million)
Table 96 Latin America: Market Size, by Route of Administration, 2016–2025 ($ Million)
Table 97 Epidemiology: Middle East & Africa
Table 98 Middle East and Africa: Market Size, by Indication, 2016–2025 ($ Million)
Table 99 Middle East and Africa: Market Size, by Type, 2016–2025 ($ Million)
Table 100 Middle East and Africa: Market Size, by Valence, 2016–2025 ($ Million)
Table 101 Middle East and Africa: Market Size, by Route of Administration, 2016–2025 ($ Million)

List of Figures
Figure 1 Key Stakeholders in the Vaccines Market
Figure 2 Research Process
Figure 3 Key Executives Interviewed
Figure 4 Primary Research Techniques
Figure 5 Market Size Estimation
Figure 6 Vaccines Market Outlook, by Indication, 2018 VS.2025
Figure 7 Vaccines Market Outlook, by Route of Administration, 2018 VS.2025
Figure 8 Vaccines Market Outlook, by Antigen/Type, 2018 VS.2025
Figure 9 Monovalent Vaccines Expected to Grow at a Highest CAGR During The forecast Period
Figure 10 Vaccines Market Outlook, by Region, 2018 VS.2025
Figure 11 Market Dynamics
Figure 12 Vaccines Portfolio of Leading Players in the Market
Figure 13 Global Disease Burden of Key Indications
Figure 14 Global Adoption of Vaccine, by Type, by Country
Figure 15 Vaccines Product Pipeline, by Phase (2018)
Figure 16 Global Vaccines Market Size, by Indication, 2018–2025 ($ Million)
Figure 17 Different Routes of Vaccine Administration
Figure 18 Vaccines Market Size, by Route of Administration, 2018–2025 ($ Million)
Figure 19 Types of Vaccines, by Antigen
Figure 20 Global Vaccines Market Size, by Type, 2018–2025 ($ Million)
Figure 21 Global Vaccines Market Size, by Valence, 2018–2025 ($ Million)
Figure 22 Asia-Pacific is Expected to Witness the Fastest Growth During the Forecast Period
Figure 23 Vaccines Market: Market Share Analysis, by Company (2017)
Figure 24 Vaccines Market: Market Share Analysis, by Brand (2017)
Figure 25 Sanofi: Financial Overview, 2015-2017
Figure 26 Merck & Co., Inc.: Financial Overview, 2015-2017
Figure 27 GlaxoSmithKline Plc (GSK): Financial Overview, 2015-2017
Figure 28 Pfizer Inc.: Financial Overview, 2015-2017
Figure 29 Johnson & Johnson (J&J): Financial Overview, 2015-2017
Figure 30 Daichi Sankyo: Financial Overview, 2015-2017
Figure 31 Takeda Pharmaceutical: Financial Overview, 2015-2017
Figure 32 CSL Limited: Financial Overview, 2015-2017
Figure 33 Emergent BioSolutions Inc: Financial Overview, 2015-2017
Figure 34 AstraZeneca: Financial Overview, 2015-2017

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AstraZeneca
  • CSL Limited
  • Daiichi Sankyo
  • Emergent Biosolutions
  • GSK
  • Johnson and Johnson
  • Merck & Co. Inc.
  • Pfizer
  • Sanofi
  • Serum Institute of India
  • Takeda
Note: Product cover images may vary from those shown
Adroll
adroll